FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 48 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Foodie Fridays: Watermelon Salad August 27, 2021 Five Questions With…Jim. April 28, 2022 For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... January 12, 2024 Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent... July 24, 2023 Load more HOT NEWS Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... Mouse Study Points to Strategy for Preserving Bone During Chemotherapy Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... Can Eating Grilled or Charred Foods Cause Cancer?
